2025至2050年全球154个国家及地区哮喘经济负担模型分析
该研究采用健康增强宏观经济模型,估算2025至2050年154个国家及地区归因于哮喘的经济负担;美国负担最大,高收入国家绝对损失和GDP占比最高,中低收入国家劳动力相关损失占比更大。
核心结论
- 哮喘造成巨大且不均衡的全球宏观经济负担,不同收入水平和区域间差异明显。
- 中低收入国家以生产力损失为主,高收入国家物质资本相关效应更重要。
- 改善哮喘预防和控制可能产生经济收益。
研究设计与样本
- 采用健康增强宏观经济模型,覆盖154个国家及地区,预测2025至2050年哮喘经济负担。
- 模型通过早死导致劳动力减少和残疾导致劳动参与率下降来捕捉劳动力损失。
- 哮喘相关医疗支出减少储蓄和投资,影响物质资本积累。
主要发现
- 中低收入国家劳动力相关损失占总成本比例更大,疾病负担下降更慢。
临床怎么用
- 各国需根据收入水平差异制定哮喘防控策略,中低收入国家应重点关注减少劳动力损失。
- 高收入国家需关注医疗支出对物质资本积累的长期影响。
- 加强哮喘预防和控制可能带来宏观经济收益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Asthma is a major chronic respiratory disease with substantial health and economic consequences worldwide; however, there is little evidence for the long-term macroeconomic effects of asthma across countries. We aimed to estimate the global economic burden attributable to asthma from 2025 to 2050 across 154 countries and territories. METHODS: We estimated the long-term economic burden of asthma using a health-augmented macroeconomic model covering 154 countries and territories from 2025 to 2050. Projected labour losses were captured through reductions in the workforce due to premature death and reduced labour force participation due to disability. Physical capital accumulation was affected by asthma-related medical spending, which reduces savings and investment, measured as asthma-attributable health expenditure. In the model, this spending reduced disposable income and savings, thereby lowering investment and slowing capital accumulation over time FINDINGS: Between 2025 and 2050, our model predicted that asthma would incur costs of approximately US$863 billion (95% uncertainty interval [UI] 615-1396; 2024 US$), corresponding to an annual gross domestic product (GDP) decline of 0·036% (0·026-0·058). The projected economic burden differed markedly across the 154 countries. The USA bore the largest burden (US$471 billion [371-655]), followed by the UK (US$45 billion [28-84]) and China (US$44 billion [27-81]). Across income groups, high-income countries accounted for the greatest absolute losses (US$712 billion [525-1105]) and highest proportional GDP losses (0·054% [0·039-0·083]), whereas low-income countries incurred absolute losses of US$5 billion (2-11). In low-income and middle-income countries (LMICs), labour-related losses accounted for a larger share of total costs and declines in disease burden were slower. INTERPRETATION: Our findings suggest that asthma imposes a substantial and uneven macroeconomic burden across countries, with differences by income level and region. Productivity reductions dominate in LMICs, whereas physical capital-related effects are more important in high-income settings. Improving asthma prevention and control could yield economic gain. FUNDING: Noncommunicable Chronic Diseases-National Science and Technology Major Project; Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences; European Commission Horizon Europe.
引用
- Cao Z, Tong X, Zheng Z, et al. Global economic burden attributable to asthma, 2025-50: a global modelling analysis of 154 countries and territories. Lancet Respir Med. 2026. PMID: 42520825. doi:10.1016/S2213-2600(26)00144-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。